Edition:
United Kingdom

Albireo Pharma Inc (ALBO.OQ)

ALBO.OQ on NASDAQ Stock Exchange Capital Market

33.43USD
18 Jun 2018
Change (% chg)

-- (--)
Prev Close
$33.43
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
22,505
52-wk High
$39.67
52-wk Low
$15.31

Chart for

About

Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. It is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI), disorders where improper flow or absorption of bile causes serious medical conditions for which... (more)

Overall

Beta: 1.41
Market Cap(Mil.): $197.28
Shares Outstanding(Mil.): 8.88
Dividend: --
Yield (%): --

Financials

  ALBO.OQ Industry Sector
P/E (TTM): -- 84.11 32.75
EPS (TTM): -10.92 -- --
ROI: -38.95 1.56 14.38
ROE: -39.21 2.43 16.07

BRIEF-Albireo Pharma Inc Files For Non-Timely 10-K ‍​

* ALBIREO PHARMA INC FILES FOR NON-TIMELY 10-K WITH THE U.S. SEC ‍​ Source text: (http://bit.ly/2pobWiJ) Further company coverage:

19 Mar 2018

BRIEF-Albireo Reports Fourth Quarter And Year-End 2017 Financial Results

* ALBIREO REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS

15 Mar 2018

BRIEF-Albireo Prices $65.0 Mln Public Offering Of Common Stock

* ALBIREO PRICES $65.0 MILLION PUBLIC OFFERING OF COMMON STOCK

25 Jan 2018

BRIEF-Albireo Pharma Says Elobixibat Approved In Japan For Treatment Of Chronic Constipation

* ALBIREO TO RECEIVE MORE THAN $55 MILLION(1) IN NONDILUTIVE CASH PAYMENTS

19 Jan 2018

BRIEF-Albireo Announces Agreement With Healthcare Royalty Partners

* ALBIREO ANNOUNCES ROYALTY MONETIZATION AGREEMENT WITH HEALTHCARE ROYALTY PARTNERS FOR ELOBIXIBAT IN JAPAN

03 Jan 2018

Earnings vs. Estimates